Log in

NYSE:KODKodiak Sciences Stock Price, Forecast & News

$48.10
+0.03 (+0.06 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$47.45
Now: $48.10
$49.03
50-Day Range
$45.05
MA: $51.32
$64.42
52-Week Range
$9.47
Now: $48.10
$82.75
Volume155,240 shs
Average Volume346,785 shs
Market Capitalization$2.14 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone650-281-0850

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$2.14 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$48.10
+0.03 (+0.06 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kodiak Sciences (NYSE:KOD) Frequently Asked Questions

How has Kodiak Sciences' stock been impacted by COVID-19 (Coronavirus)?

Kodiak Sciences' stock was trading at $53.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KOD stock has decreased by 10.7% and is now trading at $48.10.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Kodiak Sciences?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kodiak Sciences
.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Kodiak Sciences
.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NYSE:KOD) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.07.
View Kodiak Sciences' earnings history
.

What price target have analysts set for KOD?

10 Wall Street analysts have issued 12 month price targets for Kodiak Sciences' stock. Their forecasts range from $40.00 to $115.00. On average, they expect Kodiak Sciences' stock price to reach $82.90 in the next year. This suggests a possible upside of 72.3% from the stock's current price.
View analysts' price targets for Kodiak Sciences
.

Has Kodiak Sciences been receiving favorable news coverage?

Headlines about KOD stock have trended negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kodiak Sciences earned a news impact score of -2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Kodiak Sciences
.

Who are some of Kodiak Sciences' key competitors?

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), NVIDIA (NVDA), Alibaba Group (BABA), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), AT&T (T), Walt Disney (DIS) and CVS Health (CVS).

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the following people:
  • Dr. Victor Perlroth, Co-Founder, Chairman, CEO & Pres (Age 45)
  • Mr. John A. Borgeson MBA, CPA, Sr. VP & CFO (Age 57)
  • Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 46)
  • Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 42)
  • Dr. Joel Naor M.D., MSc, MBA, VP of Clinical R&D Operations

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an IPO on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers.

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "KOD."

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.90%), Alps Advisors Inc. (0.14%), Mutual of America Capital Management LLC (0.11%), First Trust Advisors LP (0.11%), Swiss National Bank (0.11%) and Raymond James & Associates (0.10%). Company insiders that own Kodiak Sciences stock include Bros Advisors Lp Baker, Hong Liang, Jason Ehrlich, Richard S Levy and Robert Profusek.
View institutional ownership trends for Kodiak Sciences
.

Which institutional investors are selling Kodiak Sciences stock?

KOD stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Arizona State Retirement System, Exane Derivatives, Swiss National Bank, and Russell Investments Group Ltd.. Company insiders that have sold Kodiak Sciences company stock in the last year include Hong Liang, and Jason Ehrlich.
View insider buying and selling activity for Kodiak Sciences
.

Which institutional investors are buying Kodiak Sciences stock?

KOD stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alps Advisors Inc., Mutual of America Capital Management LLC, Letko Brosseau & Associates Inc., Principal Financial Group Inc., Rafferty Asset Management LLC, Virtu Financial LLC, and Mackay Shields LLC. Company insiders that have bought Kodiak Sciences stock in the last two years include Bros Advisors Lp Baker, Richard S Levy, and Robert Profusek.
View insider buying and selling activity for Kodiak Sciences
.

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $48.10.

How big of a company is Kodiak Sciences?

Kodiak Sciences has a market capitalization of $2.14 billion.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is www.kodiak.com.

How can I contact Kodiak Sciences?

The company can be reached via phone at 650-281-0850.

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.